(0.13%) 5 138.25 points
(0.11%) 38 484 points
(0.18%) 17 878 points
(-0.25%) $83.64
(1.09%) $1.944
(0.30%) $2 354.20
(0.56%) $27.69
(1.57%) $936.55
(-0.15%) $0.933
(-0.33%) $10.99
(-0.27%) $0.798
(1.25%) $93.02
Live Chart Being Loaded With Signals
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis...
Stats | |
---|---|
Dagens volum | 13 884.00 |
Gjennomsnittsvolum | 52 439.00 |
Markedsverdi | 32.95M |
EPS | €0 ( 2024-04-24 ) |
Neste inntjeningsdato | ( €0 ) 2024-06-26 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -9.31 |
ATR14 | €0.00500 (0.49%) |
Abionyx Pharma SA Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Abionyx Pharma SA Økonomi
Annual | 2023 |
Omsetning: | €4.60M |
Bruttogevinst: | €600 000 (13.04 %) |
EPS: | €-0.110 |
FY | 2023 |
Omsetning: | €4.60M |
Bruttogevinst: | €600 000 (13.04 %) |
EPS: | €-0.110 |
FY | 2022 |
Omsetning: | €5.25M |
Bruttogevinst: | €636 000 (12.11 %) |
EPS: | €-0.150 |
FY | 2021 |
Omsetning: | €675 000 |
Bruttogevinst: | €259 000 (38.37 %) |
EPS: | €-0.283 |
Financial Reports:
No articles found.
Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.